Trans-portal hepatic infusion of cultured bone marrow-derived mesenchymal stem cells in a steatohepatitis murine model

Sasaki, Ryo; Takami, Taro; Fujisawa, Koichi; Matsumoto, Toshihiko; Ishikawa, Tsuyoshi; Yamamoto, Naoki; Sakaida, Isao

doi:10.3164/jcbn.20-88

Cited by 3 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, under feeding with Western diet (WD) supplemented with 5% fructose (WDF), CCl 4 reduced the induction time and aggravated liver fibrosis in FATZO mice [93]. In comparison to CDAA-treated mice, additional treatment with a single dose of CCl 4 resulted in not merely hepatic lipid deposition but also peri-hepatocellular fibrosis [94]. HFFC diet combined with a low-dose of CCl 4 injection intraperitoneally to establish a murine NASH model with extensive fibrosis and rapid HCC progression [95].…”

Section: High-fat Diet Plus Carbon Tetrachloride (Ccl 4 ) Inductionmentioning

confidence: 99%

“…Because the pathogenesis of fatty liver is diverse and heterogenous, the mouse models available have similar pathological features but not necessarily the same processes as we see in the clinic. The ARRIVE guideline which was established by the editors of major biomedical journals provides some principles for selecting the right type of animal models in scientific research 94 .…”

Section: Mouse Models Of Nafldmentioning

confidence: 99%

See 1 more Smart Citation

Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies

Fang¹,

Wang²,

Pan³

et al. 2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

The prevalence of non-alcoholic fatty liver disease (NAFLD) increases year by year, and as a consequence, NAFLD has become one of the most prevalent liver diseases worldwide. Unfortunately, no pharmacotherapies for NAFLD have been approved by the United States Food and Drug Administration despite promising pre-clinical benefits; this situation highlights the urgent need to explore new therapeutic targets for NAFLD and for the discovery of effective therapeutic drugs. The mouse is one of the most commonly used models to study human disease and develop novel pharmacotherapies due to its small size, low-cost and ease in genetic engineering. Different mouse models are used to simulate various stages of NAFLD induced by dietary and/or genetic intervention. In this review, we summarize the newly described patho-mechanisms of NAFLD and review the preclinical mouse models of NAFLD (based on the method of induction) and appraises the use of these models in anti-NAFLD drug discovery. This article will provide a useful resource for researchers to select the appropriate model for research based on the research question being addressed.

show abstract

Section: High-fat Diet Plus Carbon Tetrachloride (Ccl 4 ) Inductionmentioning

confidence: 99%

Section: Mouse Models Of Nafldmentioning

confidence: 99%

Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies

Fang¹,

Wang²,

Pan³

et al. 2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…BMMSCs showed antioxidative activity in endstage liver diseases. BMMSCs migrated into injured sites in liver fibrosis animal models [74,75], significantly reduced ROS production [76], downregulated lipid peroxidation (LPO) [75], improved SOD activity [76,77], and increased GSH [74,75] and antioxidant enzyme levels via Nrf2/HO-1 signaling pathway [75,78]. In addition to BMMSCs, human amniotic membrane-derived MSCs significantly reduced oxidative stress in decompensated liver cirrhosis [79].…”

Section: Antioxidative Capacitymentioning

confidence: 99%

Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control

Gao

Yin

Ren

2022

Stem Cells International

View full text Add to dashboard Cite

The chronic liver diseases will slowly develop into liver fibrosis, cirrhosis, and even liver cancer if no proper control is performed with high efficiency. Up to now, the most effective treatment for end-stage liver diseases is liver transplantation. However, liver transplantation has the problems of donor deficiency, low matching rate, surgical complications, high cost, and immune rejection. These problems indicate that novel therapeutic strategies are urgently required. Mesenchymal stem cells (MSCs) are somatic stem cells with multidirectional differentiation potential and self-renewal ability. MSCs can secrete a large number of cytokines, chemokines, immunomodulatory molecules, and hepatotrophic factors, as well as produce extracellular vesicles. They alleviate liver diseases by differentiating to hepatocyte-like cells, immunomodulation, homing to the injured site, regulating cell ferroptosis, regulating cell autophagy, paracrine effects, and MSC-mitochondrial transfer. In this review, we focus on the main resources of MSCs, underlying therapeutic mechanisms, clinical applications, and efforts made to improve MSC-based cell therapy efficiency.

show abstract

“…162 Similar results were confirmed by Sasaki et al, demonstrating improved liver fibrosis, liver steatosis, and oxidative stress following intraportal injection of bone marrow-derived MSCs in a steatohepatitis murine model. 163 None of these models determined preinjection portal-lung shunt values to account for cell loss.…”

Section: Delivery Routes Of Stem Cellsmentioning

confidence: 99%

Stem Cell–Based Therapies: What Interventional Radiologists Need to Know

Commander

Stavas

2021

Semin intervent Radiol

View full text Add to dashboard Cite

As the basic units of biological organization, stem cells and their progenitors are essential for developing and regenerating organs and tissue systems using their unique self-renewal capability and differentiation potential into multiple cell lineages. Stem cells are consistently present throughout the entire human development, from the zygote to adulthood. Over the past decades, significant efforts have been made in biology, genetics, and biotechnology to develop stem cell–based therapies using embryonic and adult autologous or allogeneic stem cells for diseases without therapies or difficult to treat. Stem cell–based therapies require optimum administration of stem cells into damaged organs to promote structural regeneration and improve function. Maximum clinical efficacy is highly dependent on the successful delivery of stem cells to the target tissue. Direct image-guided locoregional injections into target tissues offer an option to increase therapeutic outcomes. Interventional radiologists have the opportunity to perform a key role in delivering stem cells more efficiently using minimally invasive techniques. This review discusses the types and sources of stem cells and the current clinical applications of stem cell–based therapies. In addition, the regulatory considerations, logistics, and potential roles of interventional Radiology are also discussed with the review of the literature.

show abstract

Trans-portal hepatic infusion of cultured bone marrow-derived mesenchymal stem cells in a steatohepatitis murine model

Cited by 3 publications

References 28 publications

Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies

Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies

Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control

Stem Cell–Based Therapies: What Interventional Radiologists Need to Know

Contact Info

Product

Resources

About